A randomized, double-blind comparison of risedronate and etidronate in the treatment of paget’s disease of bone

PURPOSE: To compare the efficacy and tolerability of oral risedronate and etidronate for treatment of Paget’s disease of bone. PATIENTS AND METHODS: Patients from 12 centers in North America received risedronate 30 mg daily for 2 months (62 patients) or etidronate 400 mg daily for 6 months (61 patie...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of medicine 1999-05, Vol.106 (5), p.513-520
Hauptverfasser:	Miller, Paul D, Brown, Jacques P, Siris, Ethel S, Hoseyni, Mohammad S, Axelrod, Douglas W, Bekker, Pirow J
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological and medical sciences Bones Bones, joints and connective tissue. Antiinflammatory agents Disease Drug therapy Medical sciences Pharmacology. Drug treatments
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	PURPOSE: To compare the efficacy and tolerability of oral risedronate and etidronate for treatment of Paget’s disease of bone. PATIENTS AND METHODS: Patients from 12 centers in North America received risedronate 30 mg daily for 2 months (62 patients) or etidronate 400 mg daily for 6 months (61 patients) in a prospective, randomized, double-blind study. Serum alkaline phosphatase (the primary variable), serum bone-specific alkaline phosphatase, and urinary deoxypyridinoline concentrations were monitored for 12 to 18 months. RESULTS: Serum alkaline phosphatase concentration normalized by month 12 in 73% of risedronate-treated patients, compared with 15% of those receiving etidronate ( P 360 days for etidronate-treated patients ( P
ISSN:	0002-9343 1555-7162
DOI:	10.1016/S0002-9343(99)00062-5